Research Progress of Fruquintinib on Advanced Colorectal Cancer
10.3971/j.issn.1000-8578.2021.21.0458
- VernacularTitle:呋喹替尼在晚期结直肠癌中的研究进展
- Author:
Liying SUN
1
;
Ye MAO
;
Zhiqun HUANG
;
Shenglan HUANG
;
Dan LI
;
Jianbing WU
Author Information
1. Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang 360000, China
- Publication Type:Research Article
- Keywords:
Fruquintinib;
Antiangiogenic drugs;
Colorectal cancer
- From:
Cancer Research on Prevention and Treatment
2021;48(12):1135-1142
- CountryChina
- Language:Chinese
-
Abstract:
Fruquintinib is an effective, highly selective and oral VEGFR 1, 2 and 3 tyrosine kinase inhibitor. It was discovered and developed by Hutchison MediPharma for the treatment of solid tumors. In September 2018, fruquintinib received its first global approval in China for use in the treatment of metastatic colorectal cancer (CRC) patients who have failed at least two prior systemic anti-neoplastic therapies. Clinical studies have shown that it has the advantages of low off-target toxicity, good drug resistance and strong curative effect. This article reviews the molecular structure, mechanism of action, pharmacokinetics, clinical efficacy and safety of fruquintinib, as well as its potential clinical applications in other tumor types.
